PMID- 15582017
OWN - NLM
STAT- MEDLINE
DCOM- 20050512
LR  - 20181201
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 79
IP  - 3
DP  - 2004 Nov
TI  - Effects of MDMA administration on scopolamine-induced disruptions of learning and 
      performance in rats.
PG  - 459-72
AB  - Functional deficits following short-course high-dose administration of 
      3,4-methylenedioxymethamphetamine (MDMA) have been difficult to characterize 
      despite evidence indicating that MDMA is neurotoxic in several species. 
      Therefore, the present research used rats trained to respond under a complex 
      behavioral procedure (i.e., a multiple schedule of repeated acquisition and 
      performance of response chains), pharmacological challenge with scopolamine and 
      neurotransmitter assays to examine the effects of MDMA neurotoxicity on learning. 
      Prior to MDMA administration, 0.032-0.32 mg/kg of scopolamine produced 
      dose-dependent rate-decreasing and error-increasing effects in both components of 
      the multiple schedule. Administration of 10 mg/kg of MDMA twice per day for 4 
      days also produced rate-decreasing and error-increasing effects on these days, 
      but responding returned to baseline levels several days after the final 
      injection. In contrast to the recovery of responding, this regimen of MDMA in 
      untrained rats significantly reduced levels of both serotonin and its major 
      metabolite, 5-hydroxyindoleacetic acid (5-HIAA), for 13-14 days. Furthermore, the 
      rate-decreasing and error-increasing effects of scopolamine were significantly 
      attenuated after MDMA treatment. These results indicate that certain complex 
      operant behaviors rapidly recover from the effects of short-course high-dose MDMA 
      administration, despite the reduced levels of serotonin in the central nervous 
      system (CNS), and that this MDMA-induced loss of serotonin may affect cholinergic 
      transmission.
FAU - Winsauer, P J
AU  - Winsauer PJ
AD  - Department of Pharmacology and Experimental Therapeutics, Louisiana State 
      University Health Sciences Center, New Orleans, LA 70112-1393, USA. 
      pwinsa@lsuhsc.edu
FAU - Quinton, M S
AU  - Quinton MS
FAU - Porter, J R
AU  - Porter JR
FAU - Corll, C B
AU  - Corll CB
FAU - Moerschbaecher, J M
AU  - Moerschbaecher JM
FAU - Delatte, M S
AU  - Delatte MS
FAU - Leonard, S T
AU  - Leonard ST
FAU - Stroble, S B
AU  - Stroble SB
LA  - eng
GR  - AA09803S1/AA/NIAAA NIH HHS/United States
GR  - DA 11417/DA/NIDA NIH HHS/United States
GR  - DA 12427/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - DL48G20X8X (Scopolamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Learning/*drug effects/physiology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage
MH  - Psychomotor Performance/*drug effects/physiology
MH  - Rats
MH  - Rats, Long-Evans
MH  - Scopolamine/*pharmacology
EDAT- 2004/12/08 09:00
MHDA- 2005/05/13 09:00
CRDT- 2004/12/08 09:00
PHST- 2003/11/11 00:00 [received]
PHST- 2004/06/28 00:00 [revised]
PHST- 2004/08/20 00:00 [accepted]
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2005/05/13 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
AID - S0091-3057(04)00276-X [pii]
AID - 10.1016/j.pbb.2004.08.019 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2004 Nov;79(3):459-72. doi: 10.1016/j.pbb.2004.08.019.